Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung.
Despite good results of chemotherapy in small cell lung cancer (SCLC), occurrence of brain metastases is frequent and unaffected by commonly employed antineoplastic drugs, mainly because they do not cross the blood-brain barrier. We treated eight patients with SCLC and cerebral metastases with VM26 at 120 mg/m2 given on days 1, 3 and 5 and repeated every 3 weeks. Two patients achieved complete response and one had partial response. Mean response duration was 8.2 months and survival was more than 9 months in responding patients. Toxicity was manageable. VM26 is an active drug in SCLC with brain metastases.
Giaccone
G
G
Division of Medical Oncology, Ospedale S. Giovanni, Antica Sede, Torino, Italy.
Donadio
M
M
Bonardi
G M
GM
Testore
F
F
Calciati
A
A
D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
D013713:Teniposide; D011034:Podophyllotoxin